Screening adults for type 2 diabetes: A review of the evidence for the US Preventive Services Task Force

被引:78
作者
Harris, R
Donahue, K
Rathore, SS
Frame, P
Woolf, SH
Lohr, KN
机构
关键词
D O I
10.7326/0003-4819-138-3-200302040-00015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Type 2 diabetes mellitus is associated with a heavy burden of suffering. Screening for diabetes is controversial. Purpose: To examine the evidence that screening and earlier treatment are effective in reducing morbidity and mortality associated with diabetes. Data Sources: MEDLINE, the Cochrane Library, reviews, and experts, all of which addressed key questions about screening. Study Selection: Studies that provided information about the existence and length of an asymptomatic phase of diabetes; studies that addressed the accuracy and reliability of screening tests; and randomized, controlled trials with health outcomes for various treatment strategies were selected. Data Extraction: Two reviewers abstracted relevant information using standardized abstraction forms and graded articles according to U.S. Preventive Services Task Force criteria. Data Synthesis: No randomized, controlled trial of screening for diabetes has been performed. Type 2 diabetes mellitus includes an asymptomatic preclinical phase; the length of this phase is unknown. Screening tests can detect diabetes in its preclinical phase. Over the 10 to 15 years after clinical diagnosis, tight glycemic control probably reduces the risk for blindness and end-stage renal disease, and aggressive control of hypertension, lipid therapy, and aspirin use reduce cardiovascular events. The magnitude of the benefit is larger for cardiovascular risk reduction than for tight glycemic control. The additional benefit of starting these treatments in the preclinical phase, after detection by screening, is uncertain but is probably also greater for cardiovascular risk reduction. Conclusions: The interventions that are most clearly beneficial during the preclinical phase are those that affect the risk for cardiovascular disease. The magnitude of additional benefit of initiating tight glycemic control during the preclinical phase is uncertain but probably small.
引用
收藏
页码:215 / 229
页数:15
相关论文
共 140 条
  • [11] [Anonymous], 2000, Lancet, V355, P253, DOI DOI 10.1016/S0140-6736(99)12323-7
  • [12] The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM)
    Azad, N
    Emanuele, NV
    Abraira, C
    Henderson, WG
    Colwell, J
    Levin, SR
    Nuttall, FQ
    Comstock, JP
    Sawin, CT
    Silbert, C
    Rubino, FA
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 1999, 13 (5-6) : 307 - 313
  • [13] Is there glycemic threshold for mortality risk?
    Balkau, B
    Bertrais, S
    Ducimetiere, P
    Eschwege, E
    [J]. DIABETES CARE, 1999, 22 (05) : 696 - 699
  • [15] Tests of glycemia for the diagnosis of type 2 diabetes mellitus
    Barr, RG
    Nathan, DM
    Meigs, JB
    Singer, DE
    [J]. ANNALS OF INTERNAL MEDICINE, 2002, 137 (04) : 263 - 272
  • [16] Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorders - The Cardiovascular Health Study
    Barzilay, JI
    Spiekerman, CF
    Kuller, LH
    Burke, GL
    Bittner, V
    Gottdiener, JS
    Brancati, FL
    Orchard, TJ
    O'Leary, DH
    Savage, PJ
    [J]. DIABETES CARE, 2001, 24 (07) : 1233 - 1239
  • [17] Fasting blood glucose: An underestimated risk factor for cardiovascular death - Results from a 22-year follow-up of healthy nondiabetic men
    Bjornholt, JV
    Erikssen, G
    Aaser, E
    Sandvik, L
    Nitter-Hauge, S
    Jervell, J
    Erikssen, J
    Thaulow, E
    [J]. DIABETES CARE, 1999, 22 (01) : 45 - 49
  • [18] EVALUATION OF FASTING PLASMA-GLUCOSE AS SCREENING-TEST FOR NIDDM IN OLDER ADULTS - RANCHO BERNARDO STUDY
    BLUNT, BA
    BARRETTCONNOR, E
    WINGARD, DL
    [J]. DIABETES CARE, 1991, 14 (11) : 989 - 993
  • [19] Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes -: Implications for treatment and monitoring of metabolic control
    Bonora, E
    Calcaterra, F
    Lombardi, S
    Bonfante, N
    Formentini, G
    Bonadonna, RC
    Muggeo, M
    [J]. DIABETES CARE, 2001, 24 (12) : 2023 - 2029
  • [20] DISTINGUISHING BETWEEN PERSISTENT AND TRANSIENT IMPAIRED GLUCOSE-TOLERANCE USING A PREDICTION MODEL
    BOURN, DM
    WILLIAMS, SM
    MANN, JI
    [J]. DIABETIC MEDICINE, 1992, 9 (08) : 744 - 748